Howorth Air Tech

Howorth Air Tech is a company with a rich history dating back to 1858, and it has been an influential player in the fields of ESG, healthcare, and pharmaceuticals. Leveraging its expertise in air engineering, the company has become renowned for delivering controlled clean environments, particularly for the healthcare and pharmaceutical industries. Notably, it collaborated with Sir John Charnley to develop the world's first Ultra Clean Ventilation (UCV) system for operating theatres, marking a significant milestone in its journey. Through the evolution of its offerings, Howorth has solidified its position as a global leader in ultra clean ventilation, with the Howorth Exflow™ UCV standing out as a flagship product in this domain. Additionally, the company provides a diverse range of products and services for the medical market, demonstrating a comprehensive approach to addressing the needs of healthcare facilities. Its understanding of the stringent health and safety standards in the international biopharmaceutical and pharmaceutical sectors has led to the development of a full range of aseptic and containment barrier solutions tailored to these industries. With a focus on serving the global pharmaceutical and broader industrial markets, including process, production, biotechnology, and contract facilities, Howorth has established itself as a key player in providing world-class containment and infection control solutions. As the biotechnology industry experiences rapid growth, there is an increasing demand for facilities that cater to its specific requirements, and Howorth is well-equipped to address these needs. Overall, Howorth Air Tech's extensive experience, coupled with its understanding of the evolving demands within the healthcare, pharmaceutical, and biotechnology sectors, positions it as a compelling prospect for potential investors seeking involvement in companies driving innovation and excellence in controlled clean environments.